Fund Update: New $223.5M $NVS stock position opened by WCM INVESTMENT MANAGEMENT, LLC - Quiver Qu...

Fund Update: New $223.5M $NVS stock position opened by WCM INVESTMENT MANAGEMENT, LLC  Quiver Quantitative

After March cuts, Novartis trims another 60 roles at US headquarters - Fierce Pharma

After March cuts, Novartis trims another 60 roles at US headquarters  Fierce Pharma

Unveiling Novartis (NVS) Q1 outlook: Wall Street estimates for key metrics - MSN

Unveiling Novartis (NVS) Q1 outlook: Wall Street estimates for key metrics  MSN

NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill

NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS)  ChartMill

Global knowledge exchange in focus as NVS welcomes students from Tokyo - Karolinska Institutet

Global knowledge exchange in focus as NVS welcomes students from Tokyo  Karolinska Institutet

NVS - Novartis AG ADR Stock Price and Quote - Finviz

NVS - Novartis AG ADR Stock Price and Quote  Finviz

Novartis AG (NVS) Stock Analysis: Evaluating Growth Potential Amidst A 4.98% Upside - DirectorsTa...

Novartis AG (NVS) Stock Analysis: Evaluating Growth Potential Amidst A 4.98% Upside  DirectorsTalk Interviews

Novartis AG (NVS) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 83/100 - GuruFocus

Novartis AG (NVS) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 83/100  GuruFocus

Proposed sale of 6,800 ADS at NVS (NYSE: NVS) reported in Form 144 - Stock Titan

Proposed sale of 6,800 ADS at NVS (NYSE: NVS) reported in Form 144  Stock Titan

Novartis slips as U.S. generic erosion weighs on Q1 results (NVS:NYSE) - Seeking Alpha

Novartis slips as U.S. generic erosion weighs on Q1 results (NVS:NYSE)  Seeking Alpha

NVS SMA drug gets CHMP backing, malaria drug wins WHO prequalification - MSN

NVS SMA drug gets CHMP backing, malaria drug wins WHO prequalification  MSN

Novartis AG (NVS): One of the Best Low Risk High Growth Plays on the Market - Yahoo Finance

Novartis AG (NVS): One of the Best Low Risk High Growth Plays on the Market  Yahoo Finance

Novartis (NYSE: NVS) Q1 2026 earnings dip as key drugs surge, Avidity deal closes - Stock Titan

Novartis (NYSE: NVS) Q1 2026 earnings dip as key drugs surge, Avidity deal closes  Stock Titan

Jim Cramer is Optimistic About Novartis’ (NVS) Cancer Drug - Yahoo Finance

Jim Cramer is Optimistic About Novartis’ (NVS) Cancer Drug  Yahoo Finance

Why Analysts Are Closely Watching Novartis AG (NVS) - Yahoo Finance

Why Analysts Are Closely Watching Novartis AG (NVS)  Yahoo Finance

Novartis (NVS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance

Novartis (NVS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates  Yahoo Finance

Exploring Analyst Estimates for Novartis (NVS) Q4 Earnings, Beyond Revenue and EPS - Yahoo Finance

Exploring Analyst Estimates for Novartis (NVS) Q4 Earnings, Beyond Revenue and EPS  Yahoo Finance

Fund Update: New $108.6M $NVS stock position opened by ARROWSTREET CAPITAL, LIMITED PARTNERSHIP -...

Fund Update: New $108.6M $NVS stock position opened by ARROWSTREET CAPITAL, LIMITED PARTNERSHIP  Quiver Quantitative

Novartis: Revenue Lags In Q1, Outlook Unchanged (NYSE:NVS) - Seeking Alpha

Novartis: Revenue Lags In Q1, Outlook Unchanged (NYSE:NVS)  Seeking Alpha

Novartis cuts 114 more jobs at New Jersey HQ as restructuring rolls on - Fierce Pharma

Novartis cuts 114 more jobs at New Jersey HQ as restructuring rolls on  Fierce Pharma

Novartis: Buy Thesis Fades Into Q1 2026 Results (Rating Downgrade) (NYSE:NVS) - Seeking Alpha

Novartis: Buy Thesis Fades Into Q1 2026 Results (Rating Downgrade) (NYSE:NVS)  Seeking Alpha

Novartis pulls bid to expand Pluvicto label for prostate cancer in EU - Seeking Alpha

Novartis pulls bid to expand Pluvicto label for prostate cancer in EU  Seeking Alpha

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term  Yahoo Finance

Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report - Yahoo Finance

Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report  Yahoo Finance

Novartis (NVS) Expands Manufacturing with New Facility in North Carolina - GuruFocus

Novartis (NVS) Expands Manufacturing with New Facility in North Carolina  GuruFocus

TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029 - Yahoo Finance

TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029  Yahoo Finance

Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates  Yahoo Finance

Novartis AG (NVS) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amidst Core Income Challe...

Novartis AG (NVS) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amidst Core Income Challenges  GuruFocus

Here's Why Novartis (NVS) is a Strong Value Stock - Yahoo Finance

Here's Why Novartis (NVS) is a Strong Value Stock  Yahoo Finance

FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents - Yahoo Finance

FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents  Yahoo Finance

Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock Backed by Strong Fundamentals - Ch...

Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock Backed by Strong Fundamentals  ChartMill

NVS: FY26 Core Operating Income Expected to Decline Slightly - GuruFocus

NVS: FY26 Core Operating Income Expected to Decline Slightly  GuruFocus

Novartis (NVS) Stock Slips as Q1 Earnings Miss and CEO Flags Pricing Policy Risk - MEXC

Novartis (NVS) Stock Slips as Q1 Earnings Miss and CEO Flags Pricing Policy Risk  MEXC

Compared to Estimates, Novartis (NVS) Q3 Earnings: A Look at Key Metrics - Yahoo Finance

Compared to Estimates, Novartis (NVS) Q3 Earnings: A Look at Key Metrics  Yahoo Finance

Novartis (NVS) CEO Warns Trump Drug Pricing Policy Could Hit Global Access as Earnings Slip - Tip...

Novartis (NVS) CEO Warns Trump Drug Pricing Policy Could Hit Global Access as Earnings Slip  TipRanks

Novartis (NVS) Reports Q1 Earnings Miss with Declining Sales - GuruFocus

Novartis (NVS) Reports Q1 Earnings Miss with Declining Sales  GuruFocus

Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance

Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why  Yahoo Finance

Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110 - Yahoo Finance

Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110  Yahoo Finance

Why Novartis (NVS) is a Top Value Stock for the Long-Term - Yahoo Finance

Why Novartis (NVS) is a Top Value Stock for the Long-Term  Yahoo Finance

SA analyst upgrades/downgrades: TSLA, SMCI, NVS, KLAC - Seeking Alpha

SA analyst upgrades/downgrades: TSLA, SMCI, NVS, KLAC  Seeking Alpha

Novartis (NVS) Achieves WHO Prequalification for Coartem Baby An - GuruFocus

Novartis (NVS) Achieves WHO Prequalification for Coartem Baby An  GuruFocus

Novartis AG-Sponsored ADR (NYSE:NVS): A Methodical Pick for Steady Dividend Income - ChartMill

Novartis AG-Sponsored ADR (NYSE:NVS): A Methodical Pick for Steady Dividend Income  ChartMill

Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals - ChartMill

Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals  ChartMill

Novartis (NYSE: NVS) grows 2025 sales 8% and boosts dividend after strong pipeline gains - Stock ...

Novartis (NYSE: NVS) grows 2025 sales 8% and boosts dividend after strong pipeline gains  Stock Titan

4 stocks to watch on Friday: LLY, AMZN, NVS, UL (SP500:) - Seeking Alpha

4 stocks to watch on Friday: LLY, AMZN, NVS, UL (SP500:)  Seeking Alpha

Novartis Stock: A Mispriced Hedge In A Crowded Equity Market (NYSE:NVS) - Seeking Alpha

Novartis Stock: A Mispriced Hedge In A Crowded Equity Market (NYSE:NVS)  Seeking Alpha

Novartis Stock: Value Price, Growth Pipeline (NYSE:NVS) - Seeking Alpha

Novartis Stock: Value Price, Growth Pipeline (NYSE:NVS)  Seeking Alpha

Novartis AG (NYSE:NVS) Stands Out as a Dependable Dividend Stock with Strong Fundamentals - Chart...

Novartis AG (NYSE:NVS) Stands Out as a Dependable Dividend Stock with Strong Fundamentals  ChartMill

Novartis AG (NVS) Announces Final Two-Year Results From Phase III APPLAUSE‑IgAN Study - Yahoo Fin...

Novartis AG (NVS) Announces Final Two-Year Results From Phase III APPLAUSE‑IgAN Study  Yahoo Finance

SA analyst upgrades/downgrades: GM, UBER, UNH, NVS - Seeking Alpha

SA analyst upgrades/downgrades: GM, UBER, UNH, NVS  Seeking Alpha

Novartis (NYSE: NVS) files Form 6-K on multi-tranche USD notes - Stock Titan

Novartis (NYSE: NVS) files Form 6-K on multi-tranche USD notes  Stock Titan

Novartis (NVS) Receives Positive CHMP Opinion for Itvisma Authorization - GuruFocus

Novartis (NVS) Receives Positive CHMP Opinion for Itvisma Authorization  GuruFocus

NVS Contractual Recruitment 2026 Out, Apply Online - Adda247

NVS Contractual Recruitment 2026 Out, Apply Online  Adda247

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Dividend Investors - ChartMill

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Dividend Investors  ChartMill

Novartis (NVS) Announces New Share Buyback Program - GuruFocus

Novartis (NVS) Announces New Share Buyback Program  GuruFocus

Valve malfunction blamed for failure of Indian satellite to raise its orbit - SpaceNews

Valve malfunction blamed for failure of Indian satellite to raise its orbit  SpaceNews

Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub - Yahoo Finance

Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub  Yahoo Finance

Where is Novartis AG (NVS) Headed? - Finviz

Where is Novartis AG (NVS) Headed?  Finviz

Market Update: Microsoft (MSFT), Novartis (NVS), Coca-Cola (KO) Performance Amidst Economic Conce...

Market Update: Microsoft (MSFT), Novartis (NVS), Coca-Cola (KO) Performance Amidst Economic Concerns  GuruFocus

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case - ChartMill

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case  ChartMill

Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?  Yahoo Finance

Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree (NYSE:NVS) - Seeking ...

Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree (NYSE:NVS)  Seeking Alpha

Novartis AG (NVS) Announces US FDA Approval of Itvisma® - Yahoo Finance

Novartis AG (NVS) Announces US FDA Approval of Itvisma®  Yahoo Finance

FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents - Zacks Investment Research

FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents  Zacks Investment Research

Novartis AG (NVS): Jim Cramer Wonders Whether Its CEO Is Leaving [UPDATED] - Yahoo Finance

Novartis AG (NVS): Jim Cramer Wonders Whether Its CEO Is Leaving [UPDATED]  Yahoo Finance

Novartis (NVS) Stock Slips as Q1 Earnings Miss and CEO Flags Pricing Policy Risk - CoinCentral

Novartis (NVS) Stock Slips as Q1 Earnings Miss and CEO Flags Pricing Policy Risk  CoinCentral

NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia - Yahoo Finance

NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia  Yahoo Finance

Why Novartis (NVS) is a Top Value Stock for the Long-Term - Yahoo Finance

Why Novartis (NVS) is a Top Value Stock for the Long-Term  Yahoo Finance

TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029 - Finviz

TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029  Finviz

Novartis AG (NVS) Stock Price Down 3.66% on Mar 11 - GuruFocus

Novartis AG (NVS) Stock Price Down 3.66% on Mar 11  GuruFocus

Novartis (NVS) Stock Falls on $2B Excellergy Acquisition to Expand Allergy Portfolio - TipRanks

Novartis (NVS) Stock Falls on $2B Excellergy Acquisition to Expand Allergy Portfolio  TipRanks

Novartis to build radioligand drug site in Texas (NVS:NYSE) - Seeking Alpha

Novartis to build radioligand drug site in Texas (NVS:NYSE)  Seeking Alpha

Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Financials - ChartMill

Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Financials  ChartMill

NVS celebrates ‘America at 250’ with concert March 19 | News, Sports, Jobs - The Express - lockha...

NVS celebrates ‘America at 250’ with concert March 19 | News, Sports, Jobs - The Express  lockhaven.com

Veteran Makes the Most of ‘Rewarding’ NVS Experience - Veterans of Foreign Wars

Veteran Makes the Most of ‘Rewarding’ NVS Experience  Veterans of Foreign Wars

Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition - Yahoo Finance

Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition  Yahoo Finance

FDA approves NVS' Cosentyx in hidradenitis suppurativa for adolescents - MSN

FDA approves NVS' Cosentyx in hidradenitis suppurativa for adolescents  MSN

Novartis: Assessing The Impact Of Entresto Generics (NYSE:NVS) - Seeking Alpha

Novartis: Assessing The Impact Of Entresto Generics (NYSE:NVS)  Seeking Alpha

Novartis AG (NVS) Stock Analysis: Navigating A Steady Path With A 5.36% Potential Upside - Direct...

Novartis AG (NVS) Stock Analysis: Navigating A Steady Path With A 5.36% Potential Upside  DirectorsTalk Interviews

Novartis Stock (NVS) Climbs after Paying $3B for “Mutant”- Fighting Breast Cancer Drug - TipRanks

Novartis Stock (NVS) Climbs after Paying $3B for “Mutant”- Fighting Breast Cancer Drug  TipRanks

Novartis AG (NVS) Gets Upgraded to Overweight from Neutral by JPMorgan - Insider Monkey

Novartis AG (NVS) Gets Upgraded to Overweight from Neutral by JPMorgan  Insider Monkey

Novartis (NVS) Receives New Price Target from Morgan Stanley | N - GuruFocus

Novartis (NVS) Receives New Price Target from Morgan Stanley | N  GuruFocus

Kisqali Emerges as Novartis AG (NVS) Blockbuster with Record Q2 Growth - Yahoo Finance

Kisqali Emerges as Novartis AG (NVS) Blockbuster with Record Q2 Growth  Yahoo Finance

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case - ChartMill

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case  ChartMill

Novartis AG (NVS) Stock Analysis: Navigating Growth With A Strong 3.12% Dividend Yield - Director...

Novartis AG (NVS) Stock Analysis: Navigating Growth With A Strong 3.12% Dividend Yield  DirectorsTalk Interviews

NVS Sees Analyst Upgrade from JP Morgan to Overweight | NVS Stoc - GuruFocus

NVS Sees Analyst Upgrade from JP Morgan to Overweight | NVS Stoc  GuruFocus

Here's Why Novartis (NVS) is a Strong Momentum Stock - MSN

Here's Why Novartis (NVS) is a Strong Momentum Stock  MSN

NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth - Zacks Investment Research

NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth  Zacks Investment Research

Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy...

Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy - Slideshow  Seeking Alpha

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver - MarketBeat

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver  MarketBeat

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Strong Case for Dividend Investors - ChartMill

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Strong Case for Dividend Investors  ChartMill

Novartis: Synnovation Deal And 8% Full-Year 2025 Sales Growth (NYSE:NVS) - Seeking Alpha

Novartis: Synnovation Deal And 8% Full-Year 2025 Sales Growth (NYSE:NVS)  Seeking Alpha

Novartis AG-Sponsored ADR (NYSE:NVS): A Pillar of Dividend Reliability and Financial Health - Cha...

Novartis AG-Sponsored ADR (NYSE:NVS): A Pillar of Dividend Reliability and Financial Health  ChartMill

Novartis (NVS) Initiates Construction of New Biomedical Research Hub in San Diego - GuruFocus

Novartis (NVS) Initiates Construction of New Biomedical Research Hub in San Diego  GuruFocus

Novartis (NVS) Q4 Earnings Beat Estimates Despite Revenue Miss - GuruFocus

Novartis (NVS) Q4 Earnings Beat Estimates Despite Revenue Miss  GuruFocus

Novartis (NVS) Reports Robust Q4 Sales Growth and Pipeline Advan - GuruFocus

Novartis (NVS) Reports Robust Q4 Sales Growth and Pipeline Advan  GuruFocus

Novartis (NVS) Reports Promising Phase III Results for Fabhalta in IgA Nephropathy - GuruFocus

Novartis (NVS) Reports Promising Phase III Results for Fabhalta in IgA Nephropathy  GuruFocus

VFW Reaches $16.2 Billion Cumulative Milestone for Represented Veterans - Veterans of Foreign Wars

VFW Reaches $16.2 Billion Cumulative Milestone for Represented Veterans  Veterans of Foreign Wars

Novartis (NVS) Completes Acquisition of Avidity Biosciences - GuruFocus

Novartis (NVS) Completes Acquisition of Avidity Biosciences  GuruFocus

Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Dento...

Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Denton, Texas  Insider Monkey